These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30641802)

  • 21. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy -- a multifaceted target of new therapies.
    Choudhury D; Tuncel M; Levi M
    Discov Med; 2010 Nov; 10(54):406-15. PubMed ID: 21122472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers of diabetic nephropathy, the present and the future.
    Jim B; Santos J; Spath F; Cijiang He J
    Curr Diabetes Rev; 2012 Sep; 8(5):317-28. PubMed ID: 22698077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of inflammation in diabetic nephropathy.
    Fornoni A; Ijaz A; Tejada T; Lenz O
    Curr Diabetes Rev; 2008 Feb; 4(1):10-7. PubMed ID: 18220690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tripterygium and its extracts for diabetic nephropathy: Efficacy and pharmacological mechanisms.
    Huang WJ; Liu WJ; Xiao YH; Zheng HJ; Xiao Y; Jia Q; Jiang HX; Zhu ZB; Xia CH; Han XT; Sun RX; Nan H; Feng ZD; Wang SD; Zhao JX
    Biomed Pharmacother; 2020 Jan; 121():109599. PubMed ID: 31707345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Inhibitory Effect of Rapamycin on Toll Like Receptor 4 and Interleukin 17 in the Early Stage of Rat Diabetic Nephropathy.
    Yu R; Bo H; Villani V; Spencer PJ; Fu P
    Kidney Blood Press Res; 2016; 41(1):55-69. PubMed ID: 26849067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of diabetic nephropathy in the proteomic era.
    Thongboonkerd V
    Contrib Nephrol; 2011; 170():172-183. PubMed ID: 21659770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection and treatment of diabetic nephropathy.
    Woredekal Y
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():999-1004. PubMed ID: 18806717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
    El-Mahdy NA; El-Sayad ME; El-Kadem AH
    Biomed Pharmacother; 2016 Jul; 81():136-144. PubMed ID: 27261587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney?
    Hinden L; Tam J
    Nephron; 2019; 143(1):24-27. PubMed ID: 30636250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Future: Experimental Therapies for Renal Disease in Diabetes.
    Fouli GE; Gnudi L
    Nephron; 2019; 143(1):3-7. PubMed ID: 30257247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive advancements in the prevention and treatment of diabetic nephropathy: A narrative review.
    Elendu C; John Okah M; Fiemotongha KDJ; Adeyemo BI; Bassey BN; Omeludike EK; Obidigbo B
    Medicine (Baltimore); 2023 Oct; 102(40):e35397. PubMed ID: 37800812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.
    Mulay SR; Gaikwad AB; Tikoo K
    Chem Biol Interact; 2010 Apr; 185(2):137-42. PubMed ID: 20223228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulatory Effects of the Nutraceutical Garlic Derivative Allicin in the Progression of Diabetic Nephropathy.
    Arellano Buendía AS; Tostado González M; Sánchez Reyes O; García Arroyo FE; Argüello García R; Tapia E; Sánchez Lozada LG; Osorio Alonso H
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30314265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.